$3.59
Revenue is up for the last 3 quarters, 4.14M → 7.28M (in $), with an average increase of 24.2% per quarter
Netprofit is down for the last 2 quarters, -11.93M → -11.98M (in $), with an average decrease of 0.4% per quarter
In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 55.5%
2.23%
Downside
Day's Volatility :9.76%
Upside
7.71%
61.28%
Downside
52 Weeks Volatility :81.49%
Upside
52.2%
Period | WEREWOLF THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 44.18% | 0.9% | -8.3% |
6 Months | 105.14% | -6.8% | -6.5% |
1 Year | -12.44% | 0.4% | -6.1% |
3 Years | -77.7% | 28.3% | 21.8% |
Market Capitalization | 127.8M |
Book Value | $3.43 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.88 |
Wall Street Target Price | 11.86 |
Profit Margin | -241.79% |
Operating Margin TTM | -253.6% |
Return On Assets TTM | -18.39% |
Return On Equity TTM | -38.75% |
Revenue TTM | 20.9M |
Revenue Per Share TTM | 0.68 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -37.4M |
EBITDA | -51.5M |
Diluted Eps TTM | -1.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.69 |
EPS Estimate Next Year | -1.76 |
EPS Estimate Current Quarter | -0.5 |
EPS Estimate Next Quarter | -0.34 |
What analysts predicted
Upside of 230.36%
Sell
Neutral
Buy
WEREWOLF THERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() WEREWOLF THERAPEUTICS INC | 38.08% | 105.14% | -12.44% | -77.7% | -77.7% |
![]() Moderna, Inc. | -2.84% | -25.82% | -6.78% | 115.4% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -1.85% | -2.05% | 21.5% | 23.63% | 137.1% |
![]() Seagen, Inc. | -1.57% | 61.18% | 37.09% | 29.88% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.7% | 5.09% | 24.54% | 22.34% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() WEREWOLF THERAPEUTICS INC | 0.66 | NA | NA | -1.69 | -0.39 | -0.18 | 0.0 | 3.43 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() WEREWOLF THERAPEUTICS INC | Buy | $127.8M | -77.7% | 0.66 | -241.79% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
RA Capital Management, LLC
Mpm Asset Management, LLC
MPM Oncology Impact Management LP
Rubric Capital Management LP
Bank of America Corp
Partner Fund Management LP
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Organization | WEREWOLF THERAPEUTICS INC |
Employees | 46 |
CEO | Dr. Daniel J. Hicklin Ph.D. |
Industry | Healthcare |
ProShares Bitcoin Strategy ETF
$15.29
+1.8%
Invesco Dynamic Software ETF
$105.19
+0.54%
ARROWROOT ACQUISITION CORP-A
$10.38
-0.09%
SimilarWeb Ltd
$6.74
+3.37%
Rimini Street Inc
$4.29
+1.66%
SENTI BIOSCIENCES INC
$0.93
+5.87%
WISDOMTREE US EFFICIENT CORE
$36.20
+0.84%
XOMA CORP
$17.97
+5.64%
Madison Square Garden Entertainment Corporation
$40.09
+9.48%